Summary
A 2021 multisociety clinical guideline from the American Heart Association, American College of Cardiology, and collaborating medical organisations that synthesises contemporary literature to provide evidence-informed recommendations for chest pain evaluation and diagnosis. The guideline addresses risk stratification, appropriate diagnostic testing, and management strategies across varied clinical settings, aiming to standardise diagnostic approaches in clinical practice. As a consensus document, it does not report original research outcomes but rather collates and interprets existing evidence to guide clinician decision-making.
Regional applicability
This United States–based guideline from major American cardiology and emergency medicine organisations reflects US clinical practice standards and healthcare systems. Its recommendations may require contextualisation for United Kingdom practice, where diagnostic pathways, risk stratification tools, and access to imaging technologies differ; however, the underlying evidence synthesis and general principles of risk-based evaluation are likely transferable to inform UK guidance development.
Key measures
Recommendations for diagnostic algorithms, risk stratification protocols, and appropriate use of imaging and biomarker testing in chest pain evaluation
Outcomes reported
This guideline synthesises contemporary evidence to provide standardised recommendations for chest pain risk stratification, diagnostic testing, and management across varied clinical settings. It does not report original research outcomes but collates existing evidence to guide clinical decision-making.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.